Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep:44:102314.
doi: 10.1016/j.msard.2020.102314. Epub 2020 Jun 20.

Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab

Carlos Guevara  1 , Eduardo Villa  2 , Marcela Cifuentes  2 , Rodrigo Naves  3 , José de Grazia  2
Affiliations
Case Reports

Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab

Carlos Guevara et al. Mult Scler Relat Disord. 2020 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict of interest.

Figures

Fig. 1
Fig. 1
Last control MRI, performed in March 2020.The lesion burden remains stable in relation to the previous examinations, with multiple confluent supratentorial lesions (juxtacortical and periventricular), lesions in the posterior fossa (left middle cerebellar peduncle and right cerebellar hemisphere), one lesion at the bulbo-medullary junction and multiple spinal cord lesions (levels C4, D1 and at the conus medullaris). Lesions do not enhance with gadolinium.
Fig. 2
Fig. 2
Panel showing the timeline of the case report and laboratory data.
See this image and copyright information in PMC

References

    1. Barzegar M., Mirmosayyeb O., Nehzat N., Sarrafi R., Khorvash F., Maghzi A.-.H., Shaygannejad V. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol. Neuroimmunol. neuroinflammation. 2020;7 doi: 10.1212/NXI.0000000000000753. - DOI - PMC - PubMed
    1. Borriello G., Ianniello A. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102165. - DOI - PMC - PubMed
    1. Carandini T., Pietroboni A.M., Sacchi L., De Riz M.A., Pozzato M., Arighi A., Fumagalli G.G., Martinelli Boneschi F., Galimberti D., Scarpini E. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild uncomplicated infection despite intense immunosuppression. Mult. Scler. 2020 doi: 10.1177/1352458520926459. - DOI - PubMed
    1. Foerch C., Friedauer L., Bauer B., Wolf T., Adam E.H. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102180. - DOI - PMC - PubMed
    1. Gemcioglu E., Davutoglu M., Ozdemir E.E., Erden A. Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102196. - DOI - PMC - PubMed